Why Is Oracle Stock Falling, and is it a Buying Opportunity? | ORCL STock Analysis
Summary
Parkev analyzes Oracle's recent quarterly financial results, noting an initial negative market reaction with the stock falling over 6% post-earnings. He highlights the "phenomenal" growth in Oracle's remaining performance obligations (RPO), which increased by $85 billion to $638 billion, a 363% year-over-year surge. Despite this strong indicator, the market remains skeptical, primarily due to concerns about OpenAI's ability to fulfill its substantial contracts with Oracle. Parkev, however, views this skepticism as an opportunity, anticipating a catalyst, such as OpenAI's potential IPO, to validate these contracts and unlock significant value.
He further details Oracle's financial performance, including a 21% increase in earnings per share and revenue, with full-year fiscal 2026 revenue reaching $67.4 billion. Operating income grew 20% to $6.1 billion, resulting in a solid 33% operating profit margin. While free cash flow for the fiscal year was still negative at $24 billion, Parkev notes a crucial positive trend: operating cash flow surged 54%, and the negative free cash flow has seemingly peaked and begun to improve. He emphasizes that a significant portion of the RPO increase comes from large-scale AI contracts with customer prepayments or customer-supplied hardware, totaling $75 billion, which substantially reduces Oracle's capital expenditure requirements and counterparty risk.
Parkev acknowledges Oracle's leverage, having raised $43 billion in debt and $5 billion in equity in 2026, with plans for another $40 billion in 2027. He also points to a potential future catalyst beyond OpenAI: Oracle's belief that AI will revolutionize healthcare, creating a "ChatGPT moment" in the sector that could unlock even greater market value and improve quality of life. Based on his updated discounted cash flow valuation model, Parkev calculates Oracle's intrinsic value at $215 per share. With the stock currently trading around $189 after the post-earnings decline, he considers it undervalued and reiterates his "buy" rating, despite acknowledging the inherent risks, due to the attractive risk-reward profile at current prices.
Mentioned Stocks
Reasoning: Parkev considers Oracle stock undervalued, calculating an intrinsic value of $215 per share based on his updated discounted cash flow model, compared to the current market price of $189. He highlights the "phenomenal" 363% year-over-year growth in remaining performance obligations (RPO) to $638 billion, which includes $75 billion in customer prepayments or customer-supplied hardware for AI contracts, significantly reducing Oracle's capital requirements and risk. Although the market is skeptical about the fulfillment of large OpenAI-related contracts, Parkev views this as an opportunity, expecting a catalyst from OpenAI's potential IPO. He also notes an improvement in Oracle's free cash flow trend, which has seemingly peaked its negative trajectory, and anticipates a future "ChatGPT moment" in healthcare driven by AI as a major value driver. He reiterates his "buy" rating, citing an attractive risk-reward profile despite the associated risks.